A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.
Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.
Landry
M L
ML
Yale University, New Haven, Connecticut, USA. marie.landry@yale.edu
Stanat
S
S
Biron
K
K
Brambilla
D
D
Britt
W
W
Jokela
J
J
Chou
S
S
Drew
W L
WL
Erice
A
A
Gilliam
B
B
Lurain
N
N
Manischewitz
J
J
Miner
R
R
Nokta
M
M
Reichelderfer
P
P
Spector
S
S
Weinberg
A
A
Yen-Lieberman
B
B
Crumpacker
C
C
D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000187:drug effects* / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000821:virology*; D005347:Fibroblasts / Q000821:virology; D017245:Foscarnet / Q000494:pharmacology; D015774:Ganciclovir / Q000494:pharmacology; D006801:Humans; D007753:Laboratories / Q000592:standards; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards; D015203:Reproducibility of Results; D010948:Viral Plaque Assay / Q000379:methods* / Q000592:standards*
D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir